Hi SoT, I find myself in partial agreement only with your thoughts of D-I-Y philosophy. Whilst attractive for full revenues staying inhouse, we have to get it/them fully approved first, and there-in can lie problems. We would not be the first company with a life changing drug to suffer at the hands of FDA for not holding hands with a BP company! BP can and does gr’eze’ the wheel's thru the system and/or obfuscate the process! They also provide a ready made network for market distribution if/when approved. Pros and cons either way imho.
Hi SoT, I find myself in partial agreement only with your...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.0¢ | $353.7K | 3.309M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 74823 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.6¢ | 25218 | 3 |
View Market Depth
| Last trade - 15.58pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
10.5¢ |
Change
0.005 ( 1.16 %) |
||||
| Open | High | Low | Volume | ||
| 10.5¢ | 11.0¢ | 10.0¢ | 1085435 | ||
| Last updated 15.58pm 03/05/2024 ? | |||||
| PYC (ASX) Chart |